Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation (Q46391449)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

author name string

A Spencer

1

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

N Horvath

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

J Gibson

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

H M Prince

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

R Herrmann

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

J Bashford

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

D Joske

7

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

A Grigg

8

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

J McKendrick

9

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

I Prosser

10

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

R Lowenthal

11

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

S Deveridge

12

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

K Taylor

13

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

Australasian Leukemia and Lymphoma Group

14

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

Bone Marrow Transplantation

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

35

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

10

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

971-977

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704946

0 references

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Radiation protectors: the unexpected benefits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Amifostine (WR-2721) selective protection against melphalan genotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

21 January 2018

Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma treated with high dose intravenous melphalan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive treatment of multiple myeloma and criteria for complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Amifostine (WR-2721) Protects Normal Haematopoietic Stem Cells Against Cyclophosphamide Derivatives' Toxicity Without Compromising Their Antileukaemic Effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704946

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704946

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15778725

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46391449&oldid=2109209369"